<meta http-equiv="Content-Type" content="text/html;charset=utf-8" /><!DOCTYPE doctype html>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head>
<meta charset="UTF-8">
  <link href="./style.css" rel="stylesheet" type="text/css"/>
  <title id="pageTitle">
   # 268 Low-Dose Buprenorphine Patch for Pain
  </title>
 </head>
 <body>
   <div id="mainBody">
    <!--/pageTopArea -->
    <div id="contentArea">
     <div id="contentContainer">
      <!--/toolContainer -->
      <div id="centerZone">
       <div id="titleBarContainer">
        <h3>
         # 268 Low-Dose Buprenorphine Patch for Pain
        </h3>
       </div>
       <!--/titleBarContainer -->
       <div blockinfo="Freeform CenterZone BlockID1" class="Freeform CenterZone BlockID1">
        <p>
         <strong>
          Authors:
         </strong>
         Julie W Childers MD and Robert Arnold MD
        </p>
        <p>
         <strong>
          Background:
         </strong>
         Buprenorphine is an opioid agonist/antagonist that is used sublingually for opioid addiction treatment (see
         <em>
          Fast Fact
         </em>
         #221).  In 2010, the Food and Drug Administration approved a low-dose buprenorphine transdermal system (the ‘Butrans®’ patch) for use in the United States.  This
         <em>
          Fast Fact
         </em>
         reviews the use of buprenorphine for pain, with an emphasis on the new low-dose transdermal patch.
        </p>
        <p>
        </p>
        <p>
         <strong>
          Pharmacology:
         </strong>
         Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa- and delta
         <strong>
          -
         </strong>
         opioid receptors. It provides analgesia with decreased incidence of sedation, euphoria and respiratory depression compared to other opioids (1).  A ceiling effect for pain relief, previously identified in animals and humans, has
         <em>
          not
         </em>
         been found at the lower doses used for analgesia.  In doses available transdermally (up to 70 mcg/hour), buprenorphine does not antagonize the effect of other opioids used for breakthrough pain (2).
        </p>
        <p>
        </p>
        <p>
         <strong>
          Equianalgesic Ratios
         </strong>
         : Buprenorphine is effective parenterally for post-operative pain; 0.3 mg is equianalgesic to 10 mg IV morphine.   A trial of sublingual buprenorphine for pain (an off-label use in the U.S.) found that 0.4 mg is as effective for acute pain as 5 mg IV morphine (3). The transdermal buprenorphine to oral morphine equianalgesic ratio has been reported to be between 1:70 to 1:115 (e.g., 100 mg of oral morphine/24 hours ≈ 0.87-1.42 mg transdermal buprenorphine/24hr ≈ 36-59 mcg/hr transdermal buprenorphine).  The transdermal buprenorphine:fentanyl ratio is reported to be 0.8 mcg buprenorphine to 0.6 mcg fentanyl (4) (e.g., 20 mcg/hour of transdermal buprenorphine is approximately equivalent to 15 mcg/hour of transdermal fentanyl).
        </p>
        <p>
        </p>
        <p>
         <strong>
          Using the Low-Dose Buprenorphine Patch:
         </strong>
         The U.S. formulation of the buprenorphine transdermal system is recommended for opioid tolerant patients requiring up to 80 mg/day of oral morphine equivalents.  The patch is available in strengths of 5, 10, and 20 mcg/hour, and is worn for seven days at a time.  Buprenorphine reaches a steady state level 48 hours after application of the first patch, and, with a terminal half-life of 26 hours, levels decline slowly after patch removal. Withdrawal symptoms tend to be milder than with other long-acting opioids (5). Use of more than one patch at a time is not recommended due to risk of QT prolongation, with a mean QTc prolongation of 9.2 ms at a dose of 40 mcg/hour (6).
         <strong>
          Note:
         </strong>
         in Europe doses between 70-210 mcg/hour have been used for cancer pain with a different patch system (7).
        </p>
        <p>
        </p>
        <p>
         <strong>
          Initiating the Low-Dose Buprenorphine Patch (Manufacturer’s Recommendations) (6)
         </strong>
        </p>
        <table border="1" cellpadding="0" cellspacing="0">
         <tbody>
          <tr>
           <td style="width:294px;">
            <p>
             <strong>
              Baseline Daily Oral Morphine Equivalent
             </strong>
            </p>
           </td>
           <td style="width:234px;">
            <p>
             <strong>
              Starting Patch Dose
             </strong>
            </p>
           </td>
          </tr>
          <tr>
           <td style="width:294px;">
            <p>
             &lt;30 mg
            </p>
           </td>
           <td style="width:234px;">
            <p>
             5 mcg/hour
            </p>
           </td>
          </tr>
          <tr>
           <td style="width:294px;">
            <p>
             30-80 mg
            </p>
           </td>
           <td style="width:234px;">
            <p>
             10 mcg/hour
            </p>
           </td>
          </tr>
          <tr>
           <td style="width:294px;">
            <p>
             &gt;80 mg/day
            </p>
           </td>
           <td style="width:234px;">
            <p>
             Usage not recommended
            </p>
           </td>
          </tr>
         </tbody>
        </table>
        <p>
        </p>
        <p>
         The 20 mcg/hour patch is not intended for initial use, but patients accustomed to the patch may be titrated to this dose.
        </p>
        <p>
        </p>
        <p>
         <strong>
          Clinical Applications:
         </strong>
         The buprenorphine patch has shown to be non-inferior to other opioids in studies of chronic lower back pain, osteoarthritis, and cancer pain (8).   Because of its kappa antagonism, it has theoretical advantages in the treatment of neuropathic pain, though evidence for this is limited to case reports (9, 10).  It has also been shown experimentally to have antihyperalgesic effects (11).  Other advantages of buprenorphine include a decreased risk of respiratory depression and a lack of accumulation in renal failure, including in hemodialysis patients (12).  Some studies have reported less constipation, nausea, and sedation with buprenorphine (13,14). In a trial comparing transdermal buprenorphine in patients over 65 with younger patients, older patients had equivalent analgesia without any differences in accumulation of buprenorphine or its metabolites (15).
        </p>
        <p>
        </p>
        <p>
         <strong>
          Cost
         </strong>
         : The average wholesale price (in 2011) for a month’s supply of four 10 mcg patches is $226.
        </p>
        <p>
        </p>
        <p>
         <strong>
          Summary:
         </strong>
         The low-dose transdermal buprenorphine patch is effective for mild to moderate chronic pain, both malignant and nonmalignant.  However, given the dose limitations of the buprenorphine patch as marketed in the U.S., as well as the cost, the usefulness of this medication for most patients and clinicians is very limited.  The low-dose buprenorphine patch may be a reasonable second- or third-line option in patients with low opioid requirements who experience intolerable side effects with other opioids.
        </p>
        <p>
        </p>
        <p>
         <strong>
          References
         </strong>
        </p>
        <ol>
         <li>
          Johnson RE, Fudula PJ, Payne R.  Buprenorphine:  considerations for pain management.
          <em>
           J Pain Symptom Manage.
          </em>
          2005; 29:297-326.
         </li>
         <li>
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mercadante%20S%22%5BAuthor%5D">
           Mercadante S
          </a>
          ,
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Villari%20P%22%5BAuthor%5D">
           Villari P
          </a>
          ,
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ferrera%20P%22%5BAuthor%5D">
           Ferrera P
          </a>
          , et al. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
          <em>
           J Pain Symptom Manage.
          </em>
          2006;32:175-9.
         </li>
         <li>
          <a>
           Jalili M
          </a>
          ,
          <a>
           Fathi M
          </a>
          ,
          <a>
           Moradi-Lakeh M
          </a>
          ,
          <a>
           Zehtabchi S
          </a>
          .  Sublingual Buprenorphine in Acute Pain Management: A Double-Blind Randomized Clinical Trial.
          <em>
           Ann Emerg Med.
          </em>
          2012; 59:276-80.
          <a href="http://www.ncbi.nlm.nih.gov/pubmed/22115823">
           PMID 22115823
          </a>
          .
         </li>
         <li>
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mercadante%20S%22%5BAuthor%5D">
           Mercadante S
          </a>
          ,
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Casuccio%20A%22%5BAuthor%5D">
           Casuccio A
          </a>
          ,
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Tirelli%20W%22%5BAuthor%5D">
           Tirelli W
          </a>
          ,
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Giarratano%20A%22%5BAuthor%5D">
           Giarratano A
          </a>
          .  Equipotent doses to switch from high doses of opioids to transdermal buprenorphine.
          <a href="http://www.ncbi.nlm.nih.gov/pubmed/19104845" title="Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.">
           <em>
            Support Care Cancer.
           </em>
          </a>
          2009; 17: 715-8.
         </li>
         <li>
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Jasinski%20DR%22%5BAuthor%5D">
           Jasinski DR
          </a>
          ,
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Pevnick%20JS%22%5BAuthor%5D">
           Pevnick JS
          </a>
          ,
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Griffith%20JD%22%5BAuthor%5D">
           Griffith JD
          </a>
          . Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.
          <a href="http://www.ncbi.nlm.nih.gov/pubmed/215096" title="Archives of general psychiatry.">
           <em>
            Arch Gen Psychiatry.
           </em>
          </a>
          1978;35: 501-16.
         </li>
         <li>
          Purdue Pharma.  Available at:
          <a href="http://www.purduepharma.com/pi/prescription/ButransPI.htm">
           http://www.purduepharma.com/pi/prescription/ButransPI.htm
          </a>
          .  Accessed February 23, 2012.
         </li>
         <li>
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mercadante%20S%22%5BAuthor%5D">
           Mercadante S
          </a>
          ,
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ferrera%20P%22%5BAuthor%5D">
           Ferrera P
          </a>
          ,
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Villari%20P%22%5BAuthor%5D">
           Villari P
          </a>
          .  Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients.
          <a href="http://www.ncbi.nlm.nih.gov/pubmed/17106658" title="Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.">
           <em>
            Support Care Cancer
           </em>
           .
          </a>
          2007;15: 441-4.
         </li>
         <li>
          <a>
           Pergolizzi JV Jr
          </a>
          ,
          <a>
           Mercadante S
          </a>
          ,
          <a>
           Echaburu AV
          </a>
          , et al.  The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus.
          <em>
           Curr Med Res Opin.
          </em>
          2009; 25:1517-28.
         </li>
         <li>
          Rodriguez-Lopez M. Transdermal buprenorphine in the management of neuropathic pain.
          <em>
           Rev Soc Esp Dolor.
          </em>
          2004;11(Suppl V):11-21.
         </li>
         <li>
          Penza P, Campanella A, Martini A, et al.  Short- and intermediate-term efficacy of buprenorphine  TDS in chronic painful neuropathies.
          <em>
           J Peripher Nerv Syst
          </em>
          . 2008;13: 283-288.
         </li>
         <li>
          Koppert W, Ihmsen H, Körber N, et al. Different profiles of buprenorphine-induced hyperalgesia and antihyperalgesia in a human pain model.
          <em>
           Pain
          </em>
          . 2005;118: 15-22.
         </li>
         <li>
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Pergolizzi%20J%22%5BAuthor%5D">
           Pergolizzi J
          </a>
          ,
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Aloisi%20AM%22%5BAuthor%5D">
           Aloisi AM
          </a>
          ,
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dahan%20A%22%5BAuthor%5D">
           Dahan A
          </a>
          , et al.  Current knowledge of buprenorphine and its unique pharmacological profile.
          <a href="http://www.ncbi.nlm.nih.gov/pubmed?term=current%20knowledge%20of%20buprenorphine%20and%20its%20unique%20pharmacologic%20profile" title="Pain practice : the official journal of World Institute of Pain.">
           <em>
            Pain Pract.
           </em>
          </a>
          2010;10: 428-50.
         </li>
         <li>
          Likar R, Vadlau EM, Breschan C, Kager I, Korak-Leiter M, Ziervogel G.  Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age.
          <em>
           Clin J Pain.
          </em>
          2008;24:536-43.
         </li>
         <li>
          Bach V, Kamp-Jensen M, Jensen NH, et al. Buprenorphine and sustained release morphine – effect and side-effects in chronic use.
          <em>
           The Pain Clinic
          </em>
          . 1991;4:87–93.
         </li>
         <li>
          R. Likar, H. Kayser and R. Sittl. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
          <em>
           Clin Ther
          </em>
          <em>
           .
          </em>
          2006; 28: 943–52.
         </li>
        </ol>
        <p style="margin-left:37.5pt;">
        </p>
        <p>
         <strong>
          Conflicts of Interest Statement:
         </strong>
         The authors have no relevant conflicts of interest to disclose.
        </p>
        <p>
        </p>
        <p>
         <strong>
          Authors’ Affiliation:
         </strong>
         University of Pittsburgh Medical Center, Pittsburgh, PA.
        </p>
        <p>
        </p>
       </div>
      </div>
      <!--/centerZone -->
      <div id="rightZone">
      </div>
      <!--/rightZone -->
     </div>
     <!--/contentContainer -->
    </div>
    <!-- /contentArea -->
    <!--/bottomContainer -->
   </div>
   <!--/mainBody -->
 </body>
</html>
